Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials

• Published in: Annals of hematology 2012-03, Vol.91 (3), p.427-437
• Main Authors: Chang, Ying-Jun, Weng, Cui-Lian, Sun, Li-Xia, Zhao, Yun-Tao
• Format: Article
• Language: English
• Subjects: Adult; Bone Marrow Transplantation; Databases, Factual; Graft vs Host Disease; Hematologic Neoplasms - prevention & control; Hematologic Neoplasms - surgery; Hematology; Humans; Medicine; Medicine & Public Health; Oncology; Original Article; Peripheral Blood Stem Cell Transplantation; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-011-1299-8

Controversy remains regarding the transplant outcomes of human leukocyte antigen-identical related bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) for the treatment of patients with hematological malignancies. To provide an estimate of the effect of BMT and PBSCT on clinical outcomes in patients with hematological malignancies, we conducted a meta-analysis based on time-to-event data from 17 randomized controlled trials. PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), from 1972 through July 2010, and conference proceedings through July 2009 and reference lists, without any language restriction, of randomized trials that compared the transplant outcomes after BMT and PBSCT in patients with hematological malignancies were searched for details. Two independent reviewers extracted the data. The outcomes examined were engraftment, graft-versus-host disease (GVHD), relapse, transplant-related mortality (TRM), leukemia-free-survival (LFS), and overall survival (OS). Compared to PBSCT, BMT had lower neutrophil (HR, 2.08; 95% CI, 1.80 to 2.42; p